Overview

SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.

For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov

Our Product Pipeline

Indication
Therapeutic Candidate

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Acute NIHL
Mild to Moderate

SPI-1005

(Phase 2)

60%

Click for Status

Oral SPI-1005 reduced the severity and duration of NIHL. Multicenter Ph2b to initiate enrollment in Q3 2016. Link: Clinicaltrials.gov

Meniere’s Disease
SPI-1005

(Phase 2)

45%

Click for Status

Multicenter Ph1b enrollment initiated in Q4 2015. Expected completion Q4 2016. Link: Clinicaltrials.gov

Chemotherapy-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

Pre-clinical results demonstrated significant ability of SPI-3005 to reduce the hearing loss induced by the platinum-based chemotherapeutics. Multicenter Ph2 to initiate enrollment in Q3 2016. Link: Clinicaltrials.gov

Aminoglycoside-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

Multicenter Ph2 to initiate enrollment Q3 2016

Severe to Profoundly
Impaired

SPI-5557

(Phase 1)

20%

Click for Status

Anticipate IND filing in Q4 2017

Our Product Pipeline